# Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

> **NCT00118157** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 19 (actual)

## Conditions studied

- Estrogen Receptor Positive
- Male Breast Carcinoma
- Progesterone Receptor Positive
- Recurrent Breast Carcinoma
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Lapatinib Ditosylate
- **DRUG:** Tamoxifen Citrate

## Key facts

- **NCT ID:** NCT00118157
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2011-07
- **Final completion:** 2014-09
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2017-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00118157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00118157, "Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00118157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*